Reported Earlier, Latigo Biotherapeutics Prices Upsized $345.6M Initial Public Offering Of 19.2M Shares At $18.00 Per Share
Share
Why It Matters
Latigo Biotherapeutics is a new company that just sold shares to the public for the first time, raising about $346 million. When a company does this, it means they have money to grow their business, so watch to see if they use it wisely to develop new medicines.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.